Sonoma Pharmaceuticals Files 8-K, Confirms Nasdaq Listing

Ticker: SNOA · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1367083

Sentiment: neutral

Topics: reporting-status, listing-confirmation

Related Tickers: SNOA

TL;DR

SNOA filed a routine 8-K, confirming its Nasdaq listing and emerging growth company status. No major news.

AI Summary

Sonoma Pharmaceuticals, Inc. filed an 8-K on September 29, 2025, reporting its status as an emerging growth company. The filing indicates that the company's common stock trades under the symbol SNOA on The Nasdaq Stock Market LLC. No specific financial transactions or material events are detailed in this particular filing.

Why It Matters

This filing serves as a routine update for investors, confirming the company's reporting status and stock exchange listing. It does not contain new financial information or strategic developments.

Risk Assessment

Risk Level: low — This is a standard procedural filing with no new material information that would immediately impact the company's risk profile.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Sonoma Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is to report Sonoma Pharmaceuticals, Inc.'s status as an emerging growth company and to confirm its common stock trading on The Nasdaq Stock Market LLC under the symbol SNOA.

On what date was the earliest event reported in this filing?

The earliest event reported in this filing occurred on September 29, 2025.

What is the trading symbol for Sonoma Pharmaceuticals, Inc.'s common stock?

The trading symbol for Sonoma Pharmaceuticals, Inc.'s common stock is SNOA.

On which exchange is Sonoma Pharmaceuticals, Inc.'s common stock registered?

Sonoma Pharmaceuticals, Inc.'s common stock is registered on The Nasdaq Stock Market LLC.

Does this filing indicate any new financial transactions or material events?

No, this filing primarily serves to confirm the company's reporting status and stock exchange listing, and does not detail specific new financial transactions or material events.

Filing Stats: 675 words · 3 min read · ~2 pages · Grade level 13.6 · Accepted 2025-09-29 16:30:54

Filing Documents

01 Other Events

Item 8.01 Other Events. Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the "Company"). The presentation materials are filed hereto as Exhibit 99.1. Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the Company. These forward-looking statements are identified by the use of words such as "will," "develop," "project," "expect," and "expand," among others. Forward-looking statements in this report are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company's cash needs, fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking

01 Financial

Item 9.01 Financial (d) Exhibits . Exhibit Number Description 99.1 Investor Presentation as of September 29, 2025. 104 Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101). ___________________

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SONOMA PHARMACEUTICALS, INC. Date: September 29, 2025 By: /s/ Amy Trombly Name: Title: Amy Trombly Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing